Saturday - June 06, 2026

Category Archives: Science

Schizophrenia Pipeline Accelerates as 55+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Schizophrenia Pipeline Insight 2026” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in the Schizophrenia pipeline landscape. It covers the Schizophrenia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Schizophrenia Pipeline … Continue reading →

Gorlin Syndrome Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Gorlin Syndrome Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gorlin Syndrome pipeline landscape. It covers the Gorlin Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Renal Cell Carcinoma Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Renal Cell Carcinoma Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Expands as 70+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Graft versus Host Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 45+ Key Companies | DelveInsight

elveInsight’s, “Graft versus host disease Pipeline Insight 2026” report provides comprehensive insights about 45+ Graft Versus Host Disease Companies and 50+ pipeline drugs in Graft versus host disease pipeline landscape. It covers the Graft Versus Host Disease pipeline drug profiles, … Continue reading →

Tendinopathy Market is Expected to Witness Significant Growth by 2036 Owing to the Emergence of Novel Regenerative Therapies | DelveInsight

The market dynamics for Tendinopathy are witnessing considerable growth driven by increasing prevalence of tendon injuries, rising participation in sports and physical activities, growing aging population, and advancements in regenerative medicine approaches. Additionally, the launch of emerging therapies such as … Continue reading →

Obesity Market is Expected to Witness Significant Growth by 2036 Due to Advancements in GLP-1 Therapies and Expanding Treatment Accessibility | DelveInsight

The obesity market is experiencing substantial transformation driven by the rising global obesity burden, growing awareness regarding obesity as a chronic disease, increasing adoption of GLP-1 receptor agonists, and the emergence of next-generation metabolic therapies. The anticipated launch of innovative … Continue reading →

Hereditary Angioedema (HAE) Market is Expected to Witness Significant Growth by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Hereditary Angioedema (HAE) are witnessing considerable growth driven by increasing awareness and diagnosis rates, advancements in prophylactic and on-demand therapies, and the emergence of novel gene-editing and RNA-targeted therapies. Additionally, the launch of emerging therapies such … Continue reading →

Adrenoleukodystrophy Market is Expected to Witness Significant Growth by 2036 Owing to the Emergence of Gene and Metabolic-targeted Therapies | DelveInsight

The market dynamics for Adrenoleukodystrophy (ALD) are witnessing steady growth driven by the increasing adoption of newborn screening programs, growing awareness regarding rare neurodegenerative disorders, advancements in gene therapy approaches, and rising focus on disease-modifying treatments. Additionally, the launch of … Continue reading →

Alpha-1 Antitrypsin Deficiency Market is Anticipated to Expand Rapidly by 2034 Owing to the Emergence of Innovative Gene and RNA-based Therapies | DelveInsight

The market dynamics for Alpha-1 Antitrypsin Deficiency (AATD) are witnessing steady growth driven by the increasing prevalence of respiratory and liver diseases associated with AATD, rising awareness and diagnosis rates, and growing advancements in gene-editing and RNA-based therapies. Additionally, the … Continue reading →